Seasonal effects of the monoamine oxidase inhibitor deprenyl but not the tricyclic antidepressant imipramine in rats bred for helplessness

2016 ◽  
Vol 3 (8) ◽  
pp. 313
Author(s):  
Daniela Schulz
Keyword(s):  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Tricyclic Antidepressant ◽  
Seasonal Effects ◽  
Antidepressant Imipramine

scholarly journals Development of new antidepressants

1997 ◽  
Vol 3 (1) ◽  
pp. 46-51 ◽  
Author(s):  
Eleni Palazidou
Keyword(s):  
Monoamine Oxidase ◽  
Turning Point ◽  
Monoamine Oxidase Inhibitor ◽  
Depressive Illness ◽  
Oxidase Inhibitor ◽  
Tricyclic Antidepressant ◽  
Antituberculous Drugs ◽  
One Year

The development of the first effective antidepressants in the late 1950s marked a turning point in the treatment of depressive illness. In 1957 the monoamine oxidase inhibitor (MAOI) iproniazid was discovered by chance, while searching for new antituberculous drugs. One year later the tricyclic antidepressant (TCA) imipramine was introduced, having been developed originally as an antipsychotic. A number of other drugs were subsequently added to these two groups of antidepressants, which dominated the field for the next three decades.

The clinical relevance of treatment with antidepressants

1995 ◽  
Vol 7 (2) ◽  
pp. 52-54 ◽  
Author(s):  
W.A. Nolen
Keyword(s):  
Monoamine Oxidase ◽  
Clinical Relevance ◽  
Rating Scales ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Tricyclic Antidepressant ◽  
Statistical Evidence ◽  
Monoamine Oxidase A ◽  
Selective Serotonin ◽  
Uptake Inhibitors

Oince the discovery in the late 1950's of imipramine (Tofranil®), the first tricyclic antidepressant (TCA), and iproniazid, the first monoamine oxidase inhibitor (MAOI), many other TCAs and MAOIs, now being considered the classical antidepressants, have become available. Their effectiveness has been shown in numerous studies, although according to nowadays standards well designed studies (placebo-controlled, defined diagnostic groups, the use of standardized rating scales) with these compounds are relatively scarce.From the early 1980's the so called modern antidepressants have been introduced: the selective serotonin re-uptake inhibitors (SSRIs), the reversible selective monoamine oxidase-A inhibitors (RIMAs) and a variety of other compounds. All these drugs have been registered after their effectiveness had been shown in well designed, placebo-controlled studies. In defining the efficacy of antidepressants, registration authorities consider two aspects important: statistical evidence and clinical relevance.

The treatment of anxiety disorders: a legacy of William Sargant

1997 ◽  
Vol 12 (8) ◽  
pp. 381-386
Author(s):  
MG Gelder
Keyword(s):  
Monoamine Oxidase ◽  
Anxiety Disorders ◽  
Mode Of Action ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Tricyclic Antidepressant ◽  
Psychological Treatments ◽  
Therapeutic Value ◽  
Chronic Anxiety ◽  
Made In

SummaryIn 1962 William Sargant and his colleagues described the therapeutic value of phenelzine, a monoamine oxidase inhibitor (MAOI), in chronic anxiety disorders and in the same year Klein and Fink reported the treatment of similar conditions with imipramine, a tricyclic antidepressant. Subsequent research has confirmed these findings and demonstrated the range of similar drugs that are effective in anxiety disorders. At the time of these original observations about the drug treatment of anxiety, there were no psychological treatments of proven value but in the intervening years much progress has been made in developing behavioural and cognitive procedures. The progress in determining the mode of action of these pharmacological and psychological treatments is reviewed and the implications of the findings are considered in relation to research into the causes of the anxiety disorders and to the treatment of patients.

Sign in / Sign up

Export Citation Format

Share Document